Rallybio (RLYB) Stock Statistics & Valuation Metrics

Rallybio has a market cap or net worth of $43.43M. The enterprise value is $12.23M.

Rallybio has 5,289,675 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rallybio’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -48.28%.

The current PE Ratio of Rallybio is ―. Rallybio’s PEG ratio is 0.04.

In the last 12 months, Rallybio had revenue of 858.00K and earned -8.98M in profits. Earnings per share was -1.59.

In the last 12 months, operating cash flow was -29.81M and capital expenditures 0.00, giving a free cash flow of -29.81M billion.

Rallybio pays an annual dividend of ―, resulting in a dividend yield of ―

Rallybio upcoming earnings date is May 12, 2026, Before Open (Confirmed).

Rallybio as a current ratio of 14.50, with Debt / Equity ratio of 0.30%

In the past 12 months, Rallybio has paid 0.00 in taxes.

Rallybio EV to EBITDA ratio is 0.01, with an EV/FCF ratio of <0.01.

Rallybio has $54.74M in cash and marketable securities with $176.00K in debt, giving a net cash position of $54.56M billion.

Gross margin is 99.65%, with operating margin of -3270.86%, and net profit margin of -1046.39%.

The average price target for Rallybio is ―, which is 11.43% higher than the current price. The consensus rating is ―